CLINICAL PROSPECTS FOR USING THE Ki67 PROLIFERATION INDEX IN LYMPHOGENIC METASTASES IN BREAST CARCINOMA

DOI: https://doi.org/10.29296/25877313-2020-03-04
Issue: 
3
Year: 
2020

A.S. Balkanov Dr.Sc. (Med.), Head Department of Radiotherapy in the Section «Science», M.F. Vladimirsky Moscow Regional Clinical Research Institute E-mail: andreybalkanov@yandex.ru L.E. Gaganov Dr.Sc. (Med.), Leading Research Scientist, Department of Morphological Diagnostics, Oncology Department, M.F. Vladimirsky Moscow Regional Clinical Research Institute E-mail: 6844325@mail.ru I.D. Rozanov Research Scientist, Department of Radiotherapy, M.F. Vladimirsky Moscow Regional Clinical Research Institute E.I. Shirikov Research Scientist, Department of Radiotherapy, M.F. Vladimirsky Moscow Regional Clinical Research Institute

Вackground. The number of lymphogenic metastases in the axillary region is the most important predictor of parenchymal metastasis in breast cancer (BC). The proliferation index Ki67 (IP) in lymphogenic metastasis cells as a predictor of metastasis to parenchymal organs has not been studied enough to date. Patients and methods. Comparative analysis of IP in primary tumor cells and lymphogenic metastatic cells are done in 58 patients with luminal BC T1-4N1-3. Results. It was found that the discrepancy of IP (IPdis) in the cells of luminal BC and its lymphogenic metastases occurs in 82.8% of cases. It was found that lymphogenic metastases in the group of patients IP()dis higher than in patients IP(+)dis. However, the difference was not statistically sig-nificant. Much more detected significant IPdis. In 5 cases, a higher IP in lymphogenic metastatic cells may be the cause of diagnosis of aggressive luminal B molecular subtype of BC, followed by prediction of a higher risk of parenchymal metastasis. Conclusions. The results of comparative analysis of IP in primary tumor cells and lymphogenic metastatic cells in patients with luminal BC N1-3 in the long term can be used as a predictor of high metastatic potential and as a consequence of a short period of relapse-free survival.

Keywords: 
luminal breast cancer
lymphogenic metastases
parenchymal metastasis
Ki67 proliferation index

References: 
  1. Gurov A.N., Balkanov A.S., Katuntseva N.A., Ogneva E.Ju. Analiz onkozabolevaemosti i smertnosti naselenija Moskovskoj oblasti za 2014 god. Al'manah klinicheskoj meditsiny. 2015; 41:6-12 (Gurov A.N., Balkanov A.S., Katunceva N.A., Ogneva E.Yu. Analiz onkozabolevaemosti i smertnosti naseleniya Moskovskoj oblasti za 2014 god. Al'manah klinicheskoj mediciny. 2015; 41:6-12).
  2. Jin X., Mu P. Targeting breast cancer me-tastasis. Breast Cancer (Auckl). 2015; 9(Suppl 1):23-34. doi: 10.4137/BCBCR.S25460.
  3. Richardson L.C., Henley S.J., Miller J.W., Massetti G., Thomas C.C. Patterns and trends in age-specific black-white differences in breast cancer incidence and mortality – United States. 1999–2014. Morbidity and Mortality Weekly Re-port. 2016; 65(40):1093-1098.
  4. Lee E.S., Jung S.Y., Kim J.Y., Kim J.J., Yoo T.K., Kim Y.G., Lee K.S., Lee E.S., Kim E.K., Min J.W., Han W., Noh D.Y., Moon H.G. Identi-fying the potential long-term survivors among breast cancer patients with distant metastasis. Ann. Oncol. 2016; 27(5):828-833.
  5. Liu X., Guan Y., Zhang W., Liu S., Liu J., Wang L., Niu Y. Predictors of recurrence in breast cancer subtypes with negative lymph node in a Chinese population. Int. J. Clin. Exp. Pathol. 2014; 7(6):3202-3212.
  6. Nordenskjöld A.E., Fohlin H., Albertsson P., Arnesson L.G., Chamalidou C., Einbeigi Z., Holmberg E., Nordenskjöld B., Karlsson P. No clear effect of postoperative radiotherapy on sur-vival of breast cancer patients with one to three positive nodes. Ann. Oncol. 2015; 26(6):1149-1154.
  7. Tran H.D., Luitel K., Kim M., Zhang K., Longmore G.D., Tran D.D. Transient SNAIL1 expression is necessary for metastatic competence in breast cancer. Cancer Res. 2014; 74(21):6330–6340. doi:10.1158/0008-5472.CAN-14-0923.
  8. Jiang Y., Xu H., Zhang H., Ou X., Xu Z., Ai L., Sun L., Liu C. Nomogram for prediction of level 2 axillary lymph node metastasis in proven level 1 node-positive breast cancer patients. On-cotarget. 2017; 8(42):2389–72399. doi:10.18632/oncotarget.20395.
  9. Dowsett M., Nielsen T.O., Hern R.A., Bartlett J., Coombes R.C., Cuzick J., Ellis M., Henry N.L., Hugh J.C., Lively T., McShane L., Paik S., Penault-Llorca F., Prudkin L., Regan M., Salter J., Sotiriou C., Smith I.E., Viale G., Zujew-ski J.A., Hayes D.F. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J. Natl. Cancer Inst. 2011; 103(22):1656–1664.
  10. doi: 10.1093/jnci/djr393.
  11. Kilickap S., Kaya Y., Yucel B., Tuncer E., Babacan N.A., Elagoz S. Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer. Asian Pac. J. Cancer Prev. 2014; 15(3):1381-1385.
  12. Petrelli F., Viale G., Cabiddu M., Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res. Treat. 2015; 153(3):477-491.
  13. Karlsson P., Cole B.F., Chua B.H., Price K.N., Lindtner J., Collins J.P., Kovács A., Thürli-mann B., Crivellari D., Castiglione-Gertsch M., Forbes J.F., Gelber R.D., Goldhirsch A., Gruber G. Patterns and risk factors for locoregional fail-ures after mastectomy for breast cancer: an Inter-national Breast Cancer Study Group report. Ann. Oncol. 2012; 23:2852–2858.
  14. Viani G.A., Godoi da Silva L.B., Viana B.S. Ratients with N1 breast cancer: Who could benefit from supraclavicular fossa radiotherapy? Breast. 2014; 23(6):749-753.
  15. Mittendorf E.A., Ballman K.V., McCall L.M., Yi M., Sahin A.A., Bedrosian I., Hansen N., Gabram S., Hurd T., Giuliano A.E., Hunt K.K. Evaluation of the stage IB designation of the American Joint Committee on Cancer staging sys-tem in breast cancer. J. Clin. Oncol. 2015; 33(10):1119-1127.
  16. Zhao S., Xu L., Liu W., Lv C., Zhang K., Gao H., Wang J.,
  17. Ma R. Comparison of the expression of prognos-tic biomarkers between primary tumor and axil-lary lymph node metastases in breast cancer. Int. J. Clin. Exp. Pathol. 2015; 8(5):5744–5748.
  18. Park D., Kåresen R., Noren T., Sauer T. Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications. Virchows Arch. 2007; 451(1):11-18. doi: 10.1007/s00428-007-0435-2.
  19. Furet E., Bouchtaoui M.E., Feugeas J., Miquel C., Leboeuf C., Beytout C., Bertheau P., Rhun E., Bonneterre J., Janin A., Bousquet G. In-creased risk of brain metastases in women with breast cancer and p16 expression in metastatic lymph-nodes. Oncotarget. 2017; 8(23):37332–37341. doi: 10.18632/oncotarget.16953
  20. Tawfik K., Kimler B.F., Davis M.K., Fan F., Tawfik O. Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant. Hum. Pathol. 2013; 44(1):39-46. doi: 10.1016/j.humpath.2012.05.007.